$18.69
Arcturus Therapeutics is a biotechnology business based in the US. Arcturus Therapeutics shares (ARCT) are listed on the NASDAQ and all prices are listed in US Dollars. Arcturus Therapeutics employs 180 staff and has a trailing 12-month revenue of around $163.9 million.
Our top picks for where to buy Arcturus Therapeutics stock
How to buy Arcturus Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ARCT. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Arcturus Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Arcturus Therapeutics stock price (NASDAQ: ARCT)
Use our graph to track the performance of ARCT stocks over time.Arcturus Therapeutics shares at a glance
Latest market close | $18.69 |
---|---|
52-week range | $17.52 - $45.00 |
50-day moving average | $22.24 |
200-day moving average | $29.35 |
Wall St. target price | $69.11 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-2.69 |
Is it a good time to buy Arcturus Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Arcturus Therapeutics price performance over time
Historical closes compared with the close of $18.69 from 2024-09-06
1 week (2024-08-30) | -11.42% |
---|---|
1 month (2024-08-07) | -0.21% |
3 months (2024-06-07) | -41.26% |
6 months (2024-03-07) | -49.74% |
1 year (2023-09-07) | -39.71% |
---|---|
2 years (2022-09-07) | 26.71% |
3 years (2021-09-07) | 56.5 |
5 years (2019-09-06) | 75.82% |
Arcturus Therapeutics financials
Revenue TTM | $163.9 million |
---|---|
Gross profit TTM | $62.9 million |
Return on assets TTM | -13.6% |
Return on equity TTM | -26.47% |
Profit margin | -43.92% |
Book value | $9.56 |
Market Capitalization | $570.6 million |
TTM: trailing 12 months
Arcturus Therapeutics share dividends
We're not expecting Arcturus Therapeutics to pay a dividend over the next 12 months.
Have Arcturus Therapeutics's shares ever split?
Arcturus Therapeutics's shares were split on a 1:7 basis on 15 November 2017. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arcturus Therapeutics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Arcturus Therapeutics shares which in turn could have impacted Arcturus Therapeutics's share price.
Arcturus Therapeutics share price volatility
Over the last 12 months, Arcturus Therapeutics's shares have ranged in value from as little as $17.52 up to $45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arcturus Therapeutics's is 2.641. This would suggest that Arcturus Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Arcturus Therapeutics overview
Arcturus Therapeutics Holdings Inc. , a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Frequently asked questions
nullWhat percentage of Arcturus Therapeutics is owned by insiders or institutions?
Currently 8.472% of Arcturus Therapeutics shares are held by insiders and 93.635% by institutions. How many people work for Arcturus Therapeutics?
Latest data suggests 180 work at Arcturus Therapeutics. When does the fiscal year end for Arcturus Therapeutics?
Arcturus Therapeutics's fiscal year ends in December. Where is Arcturus Therapeutics based?
Arcturus Therapeutics's address is: 10628 Science Center Drive, San Diego, CA, United States, 92121 What is Arcturus Therapeutics's ISIN number?
Arcturus Therapeutics's international securities identification number is: US03969T1097 What is Arcturus Therapeutics's CUSIP number?
Arcturus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03969T109
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
7 best day trading platforms of 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for beginners: 11 best trading platforms to get started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 best international stock brokers to invest in foreign assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 best discount brokers of 2024 for low-cost trading and investing
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
10 best brokerage accounts for buying stocks, options and more in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question